Workflow
诺思格(301333.SZ)发布前三季度业绩,归母净利润9556.68万元,增长13.21%
R&G PharmaStudies R&G PharmaStudies (SZ:301333) 智通财经网·2025-10-28 10:09

Core Viewpoint - Norsg (301333.SZ) reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, indicating positive financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 607 million yuan, representing an 8.09% year-on-year growth [1] - The net profit attributable to shareholders of the listed company was 95.5668 million yuan, showing a year-on-year increase of 13.21% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.3334 million yuan, reflecting a year-on-year growth of 22.47% [1] - Basic earnings per share stood at 1 yuan [1]